▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3301 by analyst upside · 2026-11-13
AVTR
Avantor, Inc.
Healthcare · Market Cap $11B · P/E 31.2x
ANALYST PRICE TARGET
+11.1%
implied upside to consensus target
Current Price $15.62
Consensus Target $17.35
Bull Target $19.0
Bear Target $16.0
Analysts Covering 13
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
2
Hold
10
Sell
1
52-Week Low $7.26
52-Week High $17.45
YTD Return +36.3%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) 31.2x
Forward P/E 17.6x
EPS (TTM) $0.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $6.6B
Profit Margin 5.1%
52-WEEK RANGE
52-Week Low $7.26
52-Week High $17.45
Current Price $15.62
Bear Target $16.0
Bull Target $19.0
● Now $15.62 ● Target $17.35
TRADING DATA
Avg Volume 8.7M
YTD Return +36.3%
Analyst Count 13
Consensus Hold
Upside to Target +11.1%
Last Updated 2026-11-13

ANALYST SUMMARY

Avantor, Inc. (AVTR) is currently trading at $15.62 with a Wall Street consensus price target of $17.35, implying potential upside of 11.1% over the next 12 months. 13 analysts currently cover AVTR, with a consensus rating of Hold - 15% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $19.0, while the most cautious has a target of $16.0.

AVTR operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 36.3% year-to-date and is currently trading near the upper end of its 52-week range of $7.26 – $17.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ENSG +21.0%
The Ensign Group, Inc.
$11B · P/E 27.8x · Buy
HNGE +11.9%
Hinge Health, Inc.
$10B · P/E 32.8x · Buy
QGEN -1.0%
Qiagen N.V.
$10B · P/E 27.1x · Hold
PODD +19.6%
Insulet Corporation
$10B · P/E 24.4x · Buy
HALO +19.1%
Halozyme Therapeutics, Inc.
$11B · P/E 25.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AVTR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-29 Building track record
Barclays - Reiterated
Underweight → Underweight 2026-10-29 Building track record
Stifel - Reiterated
Hold → Hold 2026-10-29 Building track record
Baird - Reiterated
Outperform → Outperform 2026-10-29 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-10-13 Building track record
TD Cowen - Reiterated
Hold → Hold 2026-10-13 Building track record
Barclays - Reiterated
Underweight → Underweight 2026-10-07 Building track record
UBS - Reiterated
Neutral → Neutral 2026-09-09 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
20/30
Consensus clarity
26/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →